Figures
Abstract
HBsAg clearance is associated with clinical cure of chronic hepatitis B virus (HBV) infection. Quantification of HBsAg may help to predict HBsAg clearance during the natural course of HBV infection and during antiviral therapy. Most studies investigating quantitative HBsAg were performed in HBV mono-infected patients. However, the immune status is considered to be important for HBsAg decline and subsequent HBsAg loss. HIV co-infection unfavorably influences the course of chronic hepatitis B. In this cross-sectional study we investigated quantitative HBsAg in 173 HBV/HIV co-infected patients from 6 centers and evaluated the importance of immunodeficiency and antiretroviral therapy. We also compared 46 untreated HIV/HBV infected patients with 46 well-matched HBV mono-infected patients. HBsAg levels correlated with CD4 T-cell count and were higher in patients with more advanced HIV CDC stage. Patients on combination antiretroviral therapy (cART) including nucleos(t)ide analogues active against HBV demonstrated significant lower HBsAg levels compared to untreated patients. Importantly, HBsAg levels were significantly lower in patients who had a stronger increase between nadir CD4 and current CD4 T-cell count during cART. Untreated HIV/HBV patients demonstrated higher HBsAg levels than HBV mono-infected patients despite similar HBV DNA levels. In conclusion, HBsAg decline is dependent on an effective immune status. Restoration of CD4 T-cells during treatment with cART including nucleos(t)ide analogues seems to be important for HBsAg decrease and subsequent HBsAg loss.
Citation: Jaroszewicz J, Reiberger T, Meyer-Olson D, Mauss S, Vogel M, Ingiliz P, et al. (2012) Hepatitis B Surface Antigen Concentrations in Patients with HIV/HBV Co-Infection. PLoS ONE 7(8): e43143. https://doi.org/10.1371/journal.pone.0043143
Editor: James Fung, The University of Hong Kong, Hong Kong
Received: April 1, 2012; Accepted: July 17, 2012; Published: August 15, 2012
Copyright: © Jaroszewicz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the BMBF funded German Center for Infectious Disease Research (DZIF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have the following conflicts: Lamivudine, GlaxoSmithKline (GSK); Tenofovir and Emtricitabine Gilead; HBsAg test, Abbott, Roche, Siemens. Dr. Jaroszewicz received lecture fees or travel grants from Roche, Gilead and Abbott. Dr. Reiberger received support from Roche (travel grant, lecture fee, grant support), MSD (travel grant, lecture fee) and Gilead (travel grant, grant support). Dr. Meyer-Olson received lecture fees or travel grants from Abbott, Bristol Myers-Squibb, Boehringer Ingelheim, Chugai, Pfizer, Roche. Dr. Mauss received lecture fees Abbott, BMS, Gilead, Janssen, MSD, Roche, advisory board BMS, Gilead, Janssen, Roche. Dr. Vogel has been employed at Janssen-Cilag since June 2011. Dr. Ingiliz has received lecture fees/consultancy fees from Roche, MSD, Gilead, BMS, Abbott, Tibotec. Dr. Payer received support from Roche (grants, lecture fees), MSD (travel grants) and Janssen (travel grants). Dr. Stoll received lecture fees and/or consult fees by Abbott, BMS, Boehringer-Ingelheim, Glaxo-Smith-Kline, ViiV-Healthcare, Roche, Gilead, Janssen-Cilag, Tibotec, Pfizer, and Merck, Sharp & Dohme. Dr. Manns received grants, lectural fees and/or consult fees from GSK, Gilead, Novartis, BMS, and Abbott. Dr. Schmidt received grants lecture fees or consult fees from Gilead, Abbott and Roche. Dr. Flisiak received advisory Board fee from Gilead; Lecture fees from Gilead, Abbott and Roche. Dr. Wedemeyer received grants, lectural fees and/or consult fees from Gilead, Novartis, BMS, and Abbott. Dr. Wedemeyer is also Academic Editor of PLoS ONE. Dr. Peck-Radosavljevic received lecture fee/advisory board from Roche, BMS, Gilead, speaker fees/consulting fees from MSD and grant support from Roche and MSD. Dr. Rockstroh received lecture fees and consult fees from Abbott, BMS, Boehringer, Gilead, GSK, Janssen, Merck, Roche Tibotec, and ViiV. Dr. Cornberg received lecture fees and/or consult fees from GSK, Gilead, Novartis, BMS, Roche, MSD and grant support from Roche and MSD. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Introduction
Chronic Hepatitis B virus (HBV) infection affects more than 350 million people worldwide. HBsAg clearance and anti-HBs seroconversion is associated with the best outcome in patients with HBV infection [1], [2]. In the natural course of HBV infection and during antiviral therapy quantification of HBsAg is a useful tool to predict the chances for HBsAg clearance [3]. The decline of HBsAg concentrations may correlate with an effective immune response against HBV and is less dependent on direct viral suppression with HBV polymerase inhibitors. This statement is supported by data that interferon alpha induced stronger HBsAg decline compared to NA therapy [4], [5]. Moreover, in a recent study HBsAg decline during NA therapy was correlated with high baseline interferon-inducible protein-10 (IP-10) levels [6], reflecting increased activity of the endogenous interferon pathway. Highest HBsAg levels are observed in immunotolerant HBeAg positive patients while lowest are detected in HBsAg carriers [7]–[9]. The link of the immune status and HBsAg concentrations may be of even greater clinical relevance in patients co-infected with the human immunodeficiency virus (HIV). The prevalence of chronic hepatitis B virus (HBV) infection in patients with HIV infection is 6–14% due to the shared routes of transmission [10]. The natural course of HBV infection can be more severe and progression of HBV related liver cirrhosis is faster in HIV positive patients [11]. Several nucleoside and nucleotide analogues (NA), inhibitors of the HIV reverse transcriptase, are also effective against HBV. One of the most frequently used NA as backbone of combined antiretroviral therapy (cART) against HIV is tenofovir, which is highly effective against HBV [12], [13]. It has been documented that long-term therapy with tenofovir reduces the risk of liver cirrhosis in HIV/HBV co-infected patients [14]. Still, HBsAg clearance and subsequent seroconversion, which represents the ultimate goal of HBV treatment, is rare. A recent study in HIV/HBV co-infected patients documented a yearly HBsAg seroconversion rate of 2.6% [15]. Monitoring of HBsAg concentrations has so far mainly been studied in HBV mono-infected patients. Two recent studies have investigated HBsAg concentrations in HIV/HBV co-infected patients [16], [17]. Both studies documented that HBsAg levels decreased only slowly despite complete suppression of HBV DNA replication during tenofovir treatment similar to reports in mono-infected patients [3]. The smaller study including 33 patients showed that HBsAg decline was not associated with HIV parameters such as HIV RNA or CD4 T-cell count. [16]. In contrast, the larger study from France including 143 patients demonstrated that HBsAg decline during TDF therapy was influenced by HIV induced immunodeficiency [17]. In HBeAg positive patients, HBsAg decline was significantly slower in patients with CD4 T-cell count <350/mm3. This study suggests that the immune status is relevant for HBsAg decline but the body of evidence is limited.
Here we aimed to investigate the correlation of quantitative HBsAg and HIV parameters in 173 HIV/HBV co-infected patients in a cross-sectional study. Our data provide further evidence that the immune status is important for HBsAg decline.
Patients and Methods
Patients and Study Design
Two hundred and fifteen HIV/HBV co-infected patients were recruited in this multicenter, cross-sectional retrospective study in 6 centers in Germany, Austria and Poland between 2001–2011. In all subjects HIV infection (positive screening and confirmatory serological tests) and chronic hepatitis B virus infection (positive HBsAg for at least 6 months) have been documented. Participating centers included Vienna (n = 72), Hannover (n = 42), Duesseldorf (n = 36), Bonn (n = 26), Berlin (n = 21) and Bialystok (n = 8). Out of 215 patients, 42 had concomitant HCV and/or HDV infection. These patients were excluded from the analysis; the final cohort consisted of 173 HIV/HBV co-infected patients. There were 148 male (85%) patients with a median age of 40 (range 17–76 yrs), 123 (71%) were receiving combination antiretroviral therapy (cART) active against HBV for a median duration of 47 (7–95) months. Predominant route of infection was MSM (n = 93, 54%), followed by IVDU (n = 20, 12%) and heterosexual transmission (n = 14, 7%), while in 46 (n = 27%) the mode of infection was unclear or endemic. The detailed characteristics of the study cohort are given in Table 1. HIV/HBV co-infected patients not receiving cART (n = 46) were compared with HBV mono-infected subjects (n = 46) without history of anti-HBV therapy. Four untreated HIV/HBV co-infected patients could not be matched due to low HBV DNA and HBeAg positivity. The control group of HBV mono-infected patients was selected from a well-defined cohort [7] and was matched for age, gender, HBeAg status and HBV DNA concentration (Table 2), which are the most relevant factors associated with HBsAg levels [3], [7]. We analyzed HBsAg levels and HIV parameters at one time-point. In addition, nadir CD4 T-cell count was recorded.
This retrospective study was conducted in accordance with the guidelines of the Declaration of Helsinki, the principles of Good Clinical Practice and according to standards of the local ethics committees. The ethical committee of Hannover Medical School approved this research project and waived the need for written informed consent because routine diagnostic data have been analyzed anonymously.
Serum HBsAg Quantification
Serum HBsAg levels were retrospectively quantified from serum samples stored at −20°C. Serum HBsAg levels were quantified using the Abbott ARCHITECT® assay (Abbott Diagnostics, Abbott Park, IL). The test has a dynamic range of 0.05–250 IU/ml. Samples were diluted 1∶100 in horse serum and if results were >250 IU/ml, samples were retested at a higher dilution. Samples with HBsAg levels <0.05 IU/ml were retested undiluted. Results are given in IU/ml. The inter- and intra-assay variability is approximately 10% (6.7–8.8%), according to the manufacturer datasheet. In addition, 26 HIV/HBV patient samples were also tested with the Roche Elecsys assay (Roche Diagnostics GmbH, Mannheim). The correlation of both assays was excellent (r = 0.99) (Figure S1).
HBV-DNA, HIV-RNA and T-cells Measurement
HBV-DNA was quantified with COBAS AmpliPrep/COBAS TaqMan (Roche Diagnostics, Mannheim, Germany) with a lower limit of detection (LLOD) of 12 IU/mL in Hannover, Vienna, Duesseldorf and Bialystok. In Bonn and Berlin HBV DNA was quantified with the Abbott RealTime assay which has a LLOD of 10 IU/ml. HIV RNA was measured COBAS TaqMan HIV-1 Test (Roche Diagnostics, Mannheim, Germany) with LLOD of 50 copies/mL (Hannover, Vienna, Duesseldorf, Bialystok) and by Abbott Real-time HIV-1 test with LLOD 40 copies/mL (Bonn and Berlin). CD4, CD8 and CD3 T-lymphocyte counts were evaluated by flow cytometer Navios in Hannover and Duesseldorf (Beckman Coulter, Krefeld, Germany), FACS Calibur in Vienna, Berlin and Bialystok (Becton Dickinson, Heidelberg, Germany or Schwechat, Austria).
Statistical Analyses
Serum HBsAg, HBV DNA and HIV RNA levels were logarithmically transformed. Data are presented as median (10–90% CI), unless indicated. Non-parametric (distribution-free) tests were applied. Mann–Whitney U and Kruskall–Wallis ANOVA tests were used for univariate and multivariate comparisons of independent continuous variables, Fisher’s exact test for discrete variables comparison. Multivariate analyses were performed by a stepwise linear regression with HBsAg levels as dependent value. The significance level (α) was assumed for P-value <0.05 for a two-sided tests. Statistical analyses were performed with Statistica 9.0 (Statsoft, Tulsa, USA) and GraphPad Prism 5.0 (GraphPad Software, Inc, La Jolla, USA).
Results
HBsAg levels were quantified in 173 HIV/HBV co-infected patients (148 male, median age 40 yrs) recruited in 6 centers in Germany, Austria and Poland. In this large, multicenter, real-life setting cohort more than half of patients were HBeAg positive (n = 103, 59%). One hundred twenty three patients (72%) received cART active against HBV for a median duration of 47 (7–95) months. The detailed characteristics of the study cohort are presented in Table 1.
HBsAg Levels in the Entire HIV/HBV Co-infected Cohort
HBsAg levels showed a significant negative association with CD4 T-cell counts (R = −0.33, P<0.001, Fig. 1a). HBsAg levels did not correlate with CD8 T-cell counts (r = −0.08, P = 0.27). Thus, a negative association between CD4/CD8 T-cells ratio and HBsAg levels (r = −0.29, P<0.001) was analogous to the one observed between CD4 T-cell counts and HBsAg. Furthermore, the highest HBsAg levels were observed in patients with most advanced stage of HIV-infection (CDC C: 4.03, CDC B: 3.11, CDC A: 3.53 log10 IU/mL, ANOVA P = 0.01, Fig. 1b). HIV/HBV co-infected patients with CD4 T-cell count below 200/mm3 had 1 log10 IU/mL higher HBsAg levels compared to patients with higher CD4 counts (4.30 vs 3.31 log10 IU/mL, P = 0.001, Fig. 1c). Nevertheless, HBV DNA remains the most important factor associated with HBsAg levels. Patients with undetectable HBV DNA had more than 1 log10 lower HBsAg level compared to patients with detectable HBV DNA (HBsAg 2.96 vs 4.33 log10 IU/mL, P<0.0001, Fig 1d).
a) Correlation of HBsAg levels with current CD4 T-cell count in all HIV/HBV co-infected patients. b) HBsAg levels in patients with different CDC stages. c) HBsAg levels in patients with CD4 T-cell counts <200 and ≥200/mm3 and d) in patients with undetectable HBV DNA (lower limit of quantification = LLOD) versus detectable HBV DNA. P-values obtained by Spearman correlation, U-Mann Whitney and Kruskall-Wallis ANOVA tests.
HBsAg Levels in HIV/HBV Co-infected Patients Treated with cART
123 HIV/HBV co-infected patients received cART active against HBV (Table 1). Median HBsAg levels in patients on therapy were lower by almost 1 log10 in comparison to untreated individuals (3.32 vs 4.23, P<0.001, Fig 2a). Comparing HBeAg positive and HBeAg negative patients, the difference in HBsAg levels between untreated and treated HIV/HBV co-infected patients was only significant in HBeAg positive patients (HBeAg positive 4.62 vs 3.71 IU/mL, P = 0.0003; HBeAg-negative 3.53 vs 3.02 IU/mL, P = 0.20). This suggests that anti-HBV therapy has more impact on HBsAg levels in HBeAg positive patients as also seen in HBV mono-infection [18].
a) Comparison of HBsAg levels in HIV/HBV co-infected patients receiving cART and not undergoing antiviral therapy. Lack of association between HBsAg levels and b) cART duration and c) cART regimen. d) HBsAg levels in patients receiving cART with current CD4 T-cell counts <200 and ≥200/mm3. P-values obtained by Spearman correlation, U-Mann Whitney and Kruskall-Wallis ANOVA tests.
HBsAg levels were higher in cART treated patients with HBeAg positive disease compared to HBeAg negative disease (4.62 vs 3.54, P = 0.002) and HBsAg was associated with HBV DNA (r = 0.56, P<0.001), while there was no correlation with ALT activity (r = 0.08, P = 0.34). Surprisingly, neither duration of anti-HBV therapy (r = −0.06, P = 0.51, Fig 2b) nor the anti-HBV regimen (ANOVA P = 0.59, Fig 2c) was associated with HBsAg levels. On the other hand, again the stage of HIV-infection was associated with HBsAg levels, with highest levels observed in CDC-C category (A: 3.31, B: 3.03 and C: 3.77, P = 0.01).
In this large cohort of patients receiving cART an inverse correlation between HBsAg levels and CD4 T-cell counts was observed (r = −0.34, P<0.001) (Table 3). Again, this association was much more pronounced in HBeAg positive patients (r = −0.38, P = 0.001) as compared to HBeAg negative HBV-infection (r = −0.31, P = 0.04). Of note, HBsAg levels were higher in patients with CD4 T-cells <200/mm3 (4.03 vs, 3.22 log10 IU/mL, P = 0.003, Fig. 2d).
In order to confirm these findings a multiple regression analysis with HBsAg levels as dependent value was performed in HIV/HBV co-infected patients receiving cART. HBsAg levels showed the strongest association with HBV DNA (β = 0.51, P<0.001). Among other factors with marginal significance CD4 T-cell count (β = −0.21, P = 0.06) and age (β = −0.20, P = 0.06) were noted (Table 3). When we exclude HBV DNA from this analysis (because 77% of patients had undetectable HBV DNA), CD4 T-cell count was the only significant factor independently associated with HBsAg levels (β = −0.30, P = 0.006).
Finally, to explain an association between HIV related immunodeficiency and HBsAg levels in more detail we have analyzed the effect of cART induced immune restoration, in this case a difference between current CD4 T-cell count and nadir CD4 T-cell count (ΔCD4). In patients receiving cART the median CD4 T-cell count increase was 166/mm3 (16–409) and was not different between HBeAg positive and HBeAg negative patients (158 vs 182 cells/µL, P = 0.61). ΔCD4 showed a correlation with the duration of cART therapy (R = 0.25, P = 0.02) and also with HBsAg levels (R = −0.24, P = 0.02, Fig. 3a), suggesting a link between a restoration of immune functions and HBsAg levels. In patients receiving cART with ΔCD4>200/mm3 HBsAg levels were significantly lower compared to patients with ΔCD4<200/mm3 (3.31 vs 3.73 log10 IU/mL, P = 0.03, Fig. 3b). The distribution of HBeAg positive patients in the two groups was comparable (57% vs 62%, P = 0.59, respectively). The effect of immune reconstitution on HBsAg was more pronounced in HBeAg positive patients (Fig. 3c).
a) The correlation between CD4 T-cell count increase on cART (ΔCD4) and HBsAg levels (open circle denote outlier patients with delta CD4 T-cell >600/mm3 but high HBsAg concentrations. 5/6 HBeAg positive, 3/6 (50%) had initially very low nadir CD4 T-cell count (9, 38 and 95 cells/µL). b) Differences in HBsAg levels in HIV/HBV co-infected patients with ΔCD4 T-cell counts <200 and ≥200/mm3 in patients receiving cART and c) in HBeAg positive and HBeAg negative disease. P-values obtained by Spearman correlation and U-Mann Whitney tests.
HBsAg Levels in Untreated Patients with HIV/HBV Co-infection
To assess a potential influence of HIV infection on HBsAg levels, we compared HBsAg levels in 46 HIV/HBV co-infected patients not receiving anti-HBV therapy with 46 HBV mono-infected untreated individuals matched for age, sex, HBeAg status and HBV DNA concentration, which are considered the most relevant factors associated with HBsAg concentrations [3], [7] (Table 2). HBsAg levels were higher in HIV/HBV co-infected patients vs. HBV mono-infected patients (4.29 vs 3.94 log10 IU/mL, P = 0.016) despite similar HBV DNA concentration (Fig. 4a). Thus, HBsAg productivity (HBsAg/HBV-DNA ratio) was significantly higher in patients with HIV/HBV co-infection (0.83 vs 0.63, P = 0.008, Fig. 4b).
Comparison of HBsAg and HBV-DNA levels a) and HBsAg/HBVDNA b) in HIV/HBV co-infected patients not receiving cART with HBV mono-infected individuals without anti-HBV therapy matched for age, gender, HBeAg status and HBV DNA. HBsAg levels in HIV/HBV co-infected patients without cART in c) different CDC stages and d) in patients with CD4 T-cell counts <200 and ≥200/mm3. P-values obtained by U-Mann Whitney and Kruskall-Wallis ANOVA tests.
Similar to previous reports in HBV mono-infected patients [7], [8], HBsAg levels were significantly higher in HBeAg positive HIV/HBV patients compared with HBeAg negative HIV/HBV patients (4.62 vs 3.54 log10 IU/mL, P<0.001). Moreover, HBsAg levels showed a negative association with age (r = −0.28, P = 0.04) and a positive one with HBV-DNA (r = 0.37, P = 0.02). These correlations were less pronounced in HIV/HBV than in HBV mono-infected controls (r = −0.49, P<0.001 and r = 0.57, P<0.001, respectively). Not only HBV related factors influenced HBsAg concentrations. Also in untreated patients, HBsAg levels were higher in patients with more advanced stages of HIV-infection (CDC-A: 3.98, B: 4.46 and C: 4.63 log10 IU/mL, ANOVA P = 0.03, Fig. 4c). Secondly, in this limited number of patients we observed a trend towards a negative association between HBsAg levels and current CD4 T-cell counts (r = −0.24, P = 0.08). HBsAg levels tended to be higher in patients with CD4 T-cell counts below 200/mm3 (4.61 vs 4.19 log10 IU/mL, P = 0.08, Fig 4d).
Discussion
In this retrospective multi-center study we provide data on HBsAg concentrations in a large cohort of HIV/HBV co-infected patients that further support the important role of the immune status for HBsAg decline.
In the overall cohort of 173 HIV/HBV patients we show a significant negative correlation between CD4 T-cell counts and HBsAg levels (Fig. 1a). We demonstrate that patients with less than 200/mm3 CD4 T-cells had significantly higher HBsAg levels compared to patients with higher CD4 T-cell counts (Fig. 1c) supporting the hypothesis that an intact immune status is important for inhibiting HBsAg production [6].
Combination antiretroviral therapy does not only restore CD4 T-cell counts but also inhibits HBV DNA, which both are relevant factors associated with HBsAg levels, especially in HBeAg positive disease [19] (Fig. 1d). Many studies have shown that HBV suppression by NA has only a limited effect on HBsAg decrease [5], [6], [18], [20] with approximately 0.15–0.81 log10 decline after 2 years during effective entecavir or tenofovir therapy [18]. The decline was documented to be higher in HBeAg positive patients than in HBeAg negative patients. In this study, patients on cART (median duration 3.9 years) had approximately 1 log10 lower HBsAg levels compared to untreated HIV/HBV co-infected patients (Fig. 2a). Considering that 60% of the HIV/HBV patients are HBeAg positive, the effect of NA therapy seems to be in the same range as in HBV mono-infected patients. We did not find a significant association between the NA regimen and HBsAg levels (Fig. 2c) and also HBV DNA (data not shown). This is in agreement with our data in HBV mono-infected patients where we did not observe a difference between potent NA (tenofovir, entecavir) and less potent NA (lamivudine, adefovir) in HBsAg decrease [6]. We also did not observe a correlation between treatment duration and HBsAg level. This could suggest that some patients may have experienced a stronger HBsAg decline and others not at all. In HBV mono-infected patients we have shown that approximately 1/5th of patients experienced a pronounced HBsAg decline, while 28% had no decline at all during up to 9 years treatment [6]. The recent study by Thibault also confirmed that only 39% of HIV/HBV co-infected patients achieved any HBsAg decline during treatment containing tenofovir [16].
Most data suggest that direct targeting the HBV polymerase has limited impact on HBsAg levels. Nevertheless, HBV DNA suppression is important for HBsAg reduction. Also in HIV/HBV patients on cART, HBV DNA levels were the strongest factor associated with HBsAg concentrations (Table 3). After complete suppression of HBV DNA replication, some level of immune response is required to achieve further reduction of HBsAg or even HBsAg loss. In HIV co-infected patients, cART including HBV polymerase inhibitors can restore CD4 immune responses that may explain the impact on HBsAg levels in HIV/HBV patients. Importantly, the difference of nadir CD4 T-cell count and CD4 T-cell count at the time of HBsAg quantification (ΔCD4) was significantly correlated with HBsAg concentrations in patients on treatment (Fig. 3a). For example, patients with a ΔCD4 count of >200/mm3 had significant lower HBsAg levels than patients with ΔCD4<200/mm3 (Fig. 4b). Our data suggest that the effect of ΔCD4 T-cell count on HBsAg levels may be stronger in HBeAg positive patients than in HBeAg negative patients (Fig. 3c). Patients with HBeAg positive wildtype HBV infection are in an earlier stage of infection. The immune status may have more impact during earlier stages of HBV infection compared to later stages of HBV infection where T cell responses against HBV might already be exhausted [21].
The most convincing data for the important influence of the immune status on HBsAg levels is given by our data in untreated HIV/HBV co-infected patients. Here we show for the first time that HBsAg levels and HBsAg production were significantly higher in untreated HIV/HBV co-infected patients compared to a well-matched control cohort of HBV mono-infected patients (Fig. 4). Importantly, both groups had similar levels of HBV DNA, which was the strongest factor associated with HBsAg (Table 3). Also in this cohort, the highest HBsAg concentrations were observed in patients with more advanced HIV disease (Fig. 1c). Older studies published before the era of potent antiretroviral/anti-HBV treatment showed that chronic hepatitis B in co-infected patients takes a more progressive disease compared to mono-infected patients [11]. The higher HBsAg concentrations in HIV/HBV co-infected patients may be one reason for this observation as high HBsAg levels have recently been associated with disease progression independent of HBV DNA levels [22]. However, a limitation of this study is that we cannot correlate HBsAg levels with the stage of liver disease, as liver biopsies have not been performed in the majority of patients.
In conclusion our data support the hypothesis that significant HBsAg decline requires both, HBV DNA suppression and an effective immune response. This study helps to explain why immunmodulatory therapies such as IFN are more effective in reducing HBsAg levels than NA alone [5] supporting the demand for new immunomodulatory treatment concepts to increase the rates of HBsAg clearance. Our results also support the recommendations to initiate cART early in HBV/HIV co-infected patients. Restoration of the immune response in an earlier phase of HBV infection may be important to achieve significant HBsAg decline during cART including HBV polymerase inhibitors. The study has limitations due to its cross-sectional approach. HBV mutations, adherence to therapy and HBV genotypes were not considered, which may have influenced HBsAg levels. Prospective longitudinal data are necessary to validate whether CD4 immune reconstitution has an impact on HBsAg decline and which specific immunologic pathways are involved.
Supporting Information
Figure S1.
Correlation of serum HBsAg levels measured by Architect Abbott and Elecsys Roche systems in 26 HBV/HIV infected patients. P-value obtained by Spearman correlation test.
https://doi.org/10.1371/journal.pone.0043143.s001
(TIF)
Author Contributions
Conceived and designed the experiments: JJ MPM HW MC. Performed the experiments: JJ TR DMO SM MV PI BP MS. Analyzed the data: JJ HW MC. Contributed reagents/materials/analysis tools: JJ TR DMO SM MV PI BP MS MPM RES RF HW MPR JR MC. Wrote the paper: JJ HW MC. Drafting the article or critically revising it and final approval: JJ TR DMO SM MV PI BAP MS MPM RES RF HW MPR JR MC.
References
- 1. European Association for the Study of the Liver (2012) EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 57: 167–185.
- 2. Cornberg M, Jaroszewicz J, Manns MP, Wedemeyer H (2010) Treatment of chronic hepatitis B. Minerva Gastroenterol Dietol. 56: 451–465.
- 3. Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, et al. (2011) Hepatitis B surface antigen Quantification: Why and How to use it in 2011 - A Core Group Report. J Hepatol 55: 1121–31.
- 4. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, et al. (2009) Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 49: 1141–1150.
- 5. Reijnders JG, Rijckborst V, Sonneveld MJ, Scherbeijn SM, Boucher CA, et al. (2010) Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 54: 449–54.
- 6. Jaroszewicz J, Ho H, Markova A, Deterding K, Wursthorn K, et al. (2011) Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther 16: 915–924.
- 7. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, et al. (2010) Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 52: 514–522.
- 8. Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, et al. (2010) Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 52: 508–513.
- 9. Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, et al. (2010) Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 139: 483–490.
- 10. Alter MJ (2006) Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44: S6–9.
- 11. Thio CL (2003) Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis 23: 125–136.
- 12. van Bommel F, Wunsche T, Schurmann D, Berg T (2002) Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 36(2): 507–508.
- 13. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, et al. (2011) Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 140: 132–143.
- 14. Tuma P, Medrano J, Resino S, Vispo E, Madejon A, et al. (2010) Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. Antivir Ther 15: 881–886.
- 15. Martin-Carbonero L, Teixeira T, Poveda E, Plaza Z, Vispo E, et al. (2011) Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS 25: 73–79.
- 16. Thibault V, Stitou H, Desire N, Valantin MA, Tubiana R, et al. (2011) Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients. Antivir Ther 16: 199–205.
- 17. Maylin S, Boyd A, Lavocat F, Gozlan J, Lascoux-Combe C, et al. (2012) Kinetics of HBs and HBe antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-HBV infected patients. AIDS 26: 939–949.
- 18. Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL (2011) Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 204: 415–418.
- 19. Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, et al. (2010) Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 51: 1933–1944.
- 20. Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, et al. (2010) Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 52: 1611–1620.
- 21. Rehermann B (2007) Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis 27: 152–160.
- 22. Chen CJ, Lee MH, Liu J, Batrla-Utermann R, Jen CL, et al. (2011) Quantitative serum levels of hepatitis B virus DNA and surface antigen are independent risk predictors of hepatocellular carcinoma. Hepatology 54: 881A–881A.